The impact of signaling pathways stimulated by HER2 receptor on prediction of clinical outcome in metastatic breast cancer patients treated with trastuzumab

被引：0
|
作者：
Grell, P.
Svoboda, M.
Fabian, P.
Radova, L.
Dziechciarkova, M.
Palacova, M.
Nenutil, R.
Hajduch, M.
Vyzula, R.
机构：
[1] Masaryk Mem Canc Inst, Brno, Czech Republic
[2] Tomas Bata Univ Zlin, Zlin, Czech Republic
[3] Palacky Univ, CR-77147 Olomouc, Czech Republic
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.1048
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1048
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
    Disis, Mary L.
    Wallace, Danelle R.
    Gooley, Theodore A.
    Dang, Yushe
    Slota, Meredith
    Lu, Hailing
    Coveler, Andrew L.
    Childs, Jennifer S.
    Higgins, Doreen M.
    Fintak, Patricia A.
    dela Rosa, Corazon
    Tietje, Kathleen
    Link, John
    Waisman, James
    Salazar, Lupe G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4685 - 4692
  • [22] Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer
    Stemmler, H. J.
    Kahlert, S.
    Siekiera, W.
    Untch, M.
    Heinrich, B.
    Heinemann, V.
    BREAST, 2006, 15 (02): : 219 - 225
  • [23] Tolerability of the combination of lapatinib and trastuzumab in older patients with HER2 positive metastatic breast cancer
    O'Connor, Tracey
    Soto-Perez-de-Celis, Enrique
    Blanchard, Suzette
    Chapman, Andrew
    Kimmick, Gretchen
    Muss, Hyman
    Luu, Thehang
    Waisman, James R.
    Li, Daneng
    Mortimer, Joanne
    Yuan, Yuan
    Somlo, George
    Stewart, Daphne
    Katheria, Vani
    Levi, Abrahm
    Hurria, Arti
    CANCER RESEARCH, 2018, 78 (04)
  • [24] Radiolabeled trastuzumab biodistribution and serum HER2 levels in HER2-positive metastatic breast cancer patients
    Perik, Patrick J.
    Lub-de Hogge, Marjolijn N.
    Gietema, Jourik A.
    Jager, Piet L.
    Kosterink, Jos G.
    de Korte, Sander A.
    van Veldhuisen, Drik J.
    van der Graaf, Winette T.
    Sieijfer, Drik T.
    de Vries, Elisabeth G.
    ANNALS OF ONCOLOGY, 2004, 15 : 14 - 14
  • [25] A PHASE 2 STUDY OF TRASTUZUMAB EMTANSINE IN JAPANESE PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER
    Takahashi, S.
    Kashiwaba, M.
    Takao, S.
    Ito, Y.
    Doihara, H.
    Rai, Y.
    Matsubara, M.
    Kanatani, K.
    Masuda, N.
    ANNALS OF ONCOLOGY, 2013, 24 : 20 - 20
  • [26] HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-postive metastatic breast cancer
    Lee, H. J.
    Seo, A. N.
    Kim, E. J.
    Jang, M. H.
    Suh, K. J.
    Ryu, H. S.
    Kim, Y. J.
    Kim, J. H.
    Im, S-A
    Gong, G.
    Park, I. A.
    Jung, K. H.
    Park, S. Y.
    CANCER RESEARCH, 2013, 73
  • [27] HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
    Lee, Hee Jin
    Seo, An Na
    Kim, Eun Joo
    Jang, Min Hye
    Suh, Koung Jin
    Ryu, Han Suk
    Kim, Yu Jung
    Kim, Jee Hyun
    Im, Seock-Ah
    Gong, Gyungyub
    Jung, Kyung Hae
    Park, In Ae
    Park, So Yeon
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142 (06) : 755 - 766
  • [28] Impact of HER2 expression dynamics on the realworld activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
    Tarantino, Paolo
    Hughes, Melissa
    Kusmick, Ross
    Alder, Laura
    Pereslete, Alyssa
    Noteware, Laura
    Moore, Heather
    Van Swearingen, Amanda
    Li, Tianyu
    Gupta, Hersh
    Smith, Kalie
    Morganti, Stefania
    Files, Janet
    Sendrick, Kerry
    Buck, Simone
    Dillon, Deborah
    Jeselsohn, Rinath
    Li, Yvonne
    Cherniack, Andrew
    Prat, Aleix
    Chan, Nay Nwe Nyein
    Rimm, David
    Curigliano, Giuseppe
    Sammons, Sarah
    Anders, Carey
    Lin, Nancy
    Tolaney, Sara
    CANCER RESEARCH, 2024, 84 (09)
  • [29] Impact of adjuvant trastuzumab (AT) on survival in metastatic (M1) her2 positive breast cancer
    Lohrisch, C.
    Speers, C.
    Francl, M.
    Tyldesley, S.
    CANCER RESEARCH, 2013, 73
  • [30] Impact of HER2 Copy Number in IHC HER2 2+/FISH Positive Breast Cancer on Outcome of Adjuvant Trastuzumab Treatment
    Borley, A.
    Mercer, T.
    Morgan, M.
    Barrett-Lee, P.
    Jasani, B.
    JOURNAL OF PATHOLOGY, 2013, 231 : 19 - 19
12345